PPARγHigh/RXRαS427F/Y has been shown to impair the secretion of inflammatory cytokines and CD8+ T-cell infiltration and confer partial resistance to immunotherapy in both clinical datasets and animal tumor models [39]. This evidence concerns the gene CD8A and neoplasm.